INTELLIGENT BIO SOLUTIONS INC. 8-K

What Happened
On June 16, 2026, Intelligent Bio Solutions, Inc. (INBS) announced via Form 8-K (Regulation FD disclosure) that it has initiated an Interference Study to support its FDA 510(k) submission for U.S. market clearance of the Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. The company furnished the press release as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: June 16, 2026 (Form 8-K, Item 7.01, Regulation FD disclosure).
• Study: Initiation of an Interference Study specifically to support an FDA 510(k) submission.
• Product/target: Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine.
• Press release: Provided as Exhibit 99.1 to the 8-K.

Why It Matters
This Interference Study is a documented regulatory step toward a 510(k) submission, which is the pathway the company is using to seek U.S. market clearance for its codeine screening capability. For investors, progress on required studies can affect the timing of potential commercialization and U.S. market access; however, the filing does not provide results, timelines, or any assurance of FDA clearance. The 8-K simply notifies the market that the company has begun a specific study supporting its regulatory submission.